---
title: "Machine learning prediction of prostate cancer and clinically significant disease at biopsy in an"
id: "medrxiv-3-machine-learning-models-for-predicting-prostate-cancer-and-clinically"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-machine-learning-models-for-predicting-prostate-cancer-and-clinically"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1?rss=1"
published_at: "2026-08-11T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Machine learning prediction of prostate cancer and clinically significant disease at biopsy in an
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-machine-learning-models-for-predicting-prostate-cancer-and-clinically
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1?rss=1)
- **Published At:** 2026-08-11T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This preprint re-analyzes an expanded institutional cohort of prostate biopsy episodes (n = 526 pooled; 524 after excluding one non-binary outcome and one missing DRE) using contemporary machine-learning practice. - Seven predictors from the original 2019 report were retained: **age**, prior biopsy history, **PSA**, prostate volume, **digital rectal examination (DRE)**, and MRI diffusion-weighted imaging findings in the peripheral and transition zones. - Because some patients (27) contributed multiple biopsy episodes, the authors used patient-ID–grouped, stratified k-fold cross-validation (StratifiedGroupKFold from scikit-learn 1.8.0) with 3- and 5-fold splits, repeated over 10 random partitions, to avoid data leakage between folds. - Four classifiers were compared: L2-regularized **logistic regression**, **gradient boosting**, **random forest**, and a shallow multilayer perceptron (single hidden layer). - Two outcomes were modeled: detection of any **prostate cancer**, and detection of **clinically significant prostate cancer** defined as Gleason score ≥ 7. - Outcome prevalences in the 524-case sample were 55.7% (292/524) for any cancer and 39.7% (208/524) for Gleason ≥ 7. - With repeated 5-fold cross-validation, **gradient boosting** achieved the highest discrimination: mean AUC 0.826 (95% CI 0.823–0.830) for any cancer and mean AUC 0.855 (95% CI 0.852–0.859) for Gleason ≥ 7. - Random forest and logistic regression gave similar performance (AUCs in the 0.81–0.85 range); the shallow multilayer perceptron performed worse and less consistently (any-cancer AUC 0.671; Gleason ≥ 7 AUC 0.742) and did not outperform the deeper five-hidden-layer ANN reported in 2019. - Results were essentially unchanged using 3-fold cross-validation. - The authors conclude that regularized logistic regression, gradient boosting, and random forest discriminated biopsy-detected prostate cancer at least as well as the previously reported multilayer ANN while using simpler models and proper separation of hyperparameter tuning from performance estimation; a shallow neural network showed no advantage in this sample size. - The study reports IRB approval (Kanto Rosai Hospital, protocol code 201730, approved March 8, 2018) and states the datasets are not publicly available due to ethical/privacy restrictions. The manuscript is a preprint and has not undergone external peer review.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=o6NvvPzlVW2FvDQ0e4iIx6AaDJW4MhivWnCvqpTFkEw-1786451384.6702573-1.2.1.1-zSgFS1WYrhIZduNNBEapf_Va_fLFasSUv_z2cH4CUGG4e1OkoYfPi5VBRwz0xjoh) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Machine learning models for predicting prostate cancer and clinically significant prostate cancer at biopsy: An updated analysis of an expanded Japanese cohort [ View ORCID Profile](http://orcid.org/0000-0002-8769-5305)Takumi Takeuchi, Akira Nomiya doi: https://doi.org/10.64898/2026.08.09.26360024 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Takumi Takeuchi Kanto Rosai Hospital * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Takumi%2BTakeuchi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Takeuchi%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATakumi%2BTakeuchi%2B) * [ORCID record for Takumi Takeuchi](http://orcid.org/0000-0002-8769-5305 "Open in new tab") * For correspondence: takeuchit@abelia.ocn.ne.jp Akira Nomiya Kanto Rosai Hospital * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Akira%2BNomiya%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nomiya%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAkira%2BNomiya%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1275862/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1275862/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1275862/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1275862/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1275862/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background: A 2019 report from our institution described a multilayer artificial neural network (ANN) for predicting prostate cancer at biopsy in 334 patients, trained with TensorFlow 1.x and evaluated at three fixed step counts without separating hyperparameter selection from test evaluation. We re-analyzed an expanded cohort from the same institution using contemporary machine-learning practice. Methods: We pooled all available biopsy episodes from the same institutional database (n = 526; 524 after excluding one non-binary outcome code and one record with missing digital rectal examination [DRE] data), retaining the same seven predictors used in the original report (age, prior biopsy history, PSA, prostate volume, DRE, and MRI diffusion-weighted imaging findings in the peripheral and transition zones). Because 27 patients contributed more than one biopsy episode, we used patient-ID-grouped, stratified k-fold cross-validation (StratifiedGroupKFold; scikit-learn 1.8.0) with 3 and 5 folds, repeated over 10 random partitions, to avoid leakage between folds. Four classifiers were compared: L2-regularized logistic regression, gradient boosting, random forest, and a shallow (single hidden layer) multilayer perceptron. Two outcomes were modeled: detection of any prostate cancer, and detection of clinically significant prostate cancer (Gleason score ≥ 7). Results: Any-cancer prevalence was 55.7% (292/524) and Gleason score ≥ 7 prevalence was 39.7% (208/524). With repeated 5-fold cross-validation, gradient boosting gave the highest discrimination for any prostate cancer (mean AUC 0.826, 95% CI 0.823-0.830) and for Gleason score ≥ 7 (mean AUC 0.855, 95% CI 0.852-0.859), closely followed by random forest and logistic regression (AUC 0.81-0.85). The shallow multilayer perceptron performed worse and less consistently than the other three models (any-cancer AUC 0.671; Gleason score ≥ 7 AUC 0.742) and than the deeper five-hidden-layer ANN reported in 2019. Results with 3-fold cross-validation were essentially unchanged. Conclusions: In an expanded cohort, regularized logistic regression, gradient boosting, and random forest all discriminated prostate cancer at biopsy at least as well as the previously reported multilayer ANN, using far simpler models and a methodology that separates hyperparameter tuning from performance estimation. A shallow neural network offered no advantage over these simpler alternatives in this sample size. This is a preprint; the study has not undergone external peer review. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethical Committee of the Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital (protocol code 201730, approved March 8, 2018). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The datasets used during the current study are not publicly available due to ethical restrictions and the privacy of the participants. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.09.26360019v1 "Quantifying Academic Risk Factors for Student Depression Using WHO Frameworks: Odds Ratios, SHAP Explainability, and Tipping Point Analysis")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.10.26360065v1 "Protocol for the Development and Prospective Evaluation of ASHA Assist India: An AI-Assisted Mobile Platform for Community-Based Stroke Prevention in Rural India") Posted August 11, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/11/2026.08.09.26360024.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.09.26360024v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/11/2026.08.09.26360024.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Machine learning models for predicting prostate cancer and clinically significant prostate cancer at biopsy: An updated analysis of an expanded Japanese cohort Takumi Takeuchi, Akira Nomiya medRxiv 2026.08.09.26360024; doi: https://doi.org/10.64898/2026.08.09.26360024 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.09.26360024v1%26text%3DMachine%2520learning%2520models%2520for%2520predicting%2520prostate%2520cancer%2520and%2520clinically%2520significant%2520prostate%2520cancer%2520at%2520biopsy%253A%2520An%2520updated%2520analysis%2520of%2520an%2520expanded%2520Japanese%2520cohort "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.09.26360024v1%26t%3DMachine%2520learning%2520models%2520for%2520predicting%2520prostate%2520cancer%2520and%2520clinically%2520significant%2520prostate%2520cancer%2520at%2520biopsy%253A%2520An%2520updated%2520analysis%2520of%2520an%2520expanded%2520Japanese%2520cohort "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.09.26360024v1%26title%3DMachine%2520learning%2520models%2520for%2520predicting%2520prostate%2520cancer%2520and%2520clinically%2520significant%2520prostate%2520cancer%2520at%2520biopsy%253A%2520An%2520updated%2520analysis%2520of%2520an%2520expanded%2520Japanese%2520cohort%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.09.26360024v1%26title%3DMachine%2520learning%2520models%2520for%2520predicting%2520prostate%2520cancer%2520and%2520clinically%2520significant%2520prostate%2520cancer%2520at%2520biopsy%253A%2520An%2520updated%2520analysis%2520of%2520an%2520expanded%2520Japanese%2520cohort "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.09.26360024) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.09.26360024v1&count=horizontal&via=&text=Machine%20learning%20models%20for%20predicting%20prostate%20cancer%20and%20clinically%20significant%20prostate%20cancer%20at%20biopsy%3A%20An%20updated%20analysis%20of%20an%20expanded%20Japanese%20cohort&counturl=www.medrxiv.org/content/10.64898/2026.08.09.26360024v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (601) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (322) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4707) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (467) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (403) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (632) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1599) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15697) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1185) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6903) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (722) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1039) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4891) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1415) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1712) * [Hematology](https://www.medrxiv.org/collection/hematology) (570) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1313) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16175) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1151) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (653) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (710) * [Neurology](https://www.medrxiv.org/collection/neurology) (7077) * [Nursing](https://www.medrxiv.org/collection/nursing) (358) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1062) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1212) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (989) * [Oncology](https://www.medrxiv.org/collection/oncology) (3528) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1017) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (383) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (436) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (460) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (136) * [Pathology](https://www.medrxiv.org/collection/pathology) (696) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1757) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (726) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (753) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5755) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9583) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2340) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1412) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1231) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (629) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (758) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (569) * [Surgery](https://www.medrxiv.org/collection/surgery) (753) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (105) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (300) * [Urology](https://www.medrxiv.org/collection/urology) (279) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which participating organizations post peer reviews of manuscripts they are evaluating _There is no TRiP material for this paper._ Community Reviews medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Community reviews for this article: _There are no community reviews for this paper._ Automated Evaluations Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv. Automated Evaluations: _There are no automated evaluations for this paper._ Blog/Media Links medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors. Video medRxiv partners with conferences and institutions to d
## Related Clinical Research

- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)
- [Adjusting unmet need for contraception by including husband’s virility in the Revised algorithm](https://medichelpline.com/clinical-feed/plos-one-2-incorporating-husband-s-influence-in-estimating-unmet-need-for-contraception.md)
- [Pre-diagnostic 1-year prevalence of polypharmacy and PIMcog in Norwegian outpatients with MCI or d](https://medichelpline.com/clinical-feed/plos-one-14-one-year-pre-diagnostic-prevalence-and-associated-factors-of-polypharmacy-and.md)
- [Multiple Long-Term Conditions in India: Prevalence, Quality of Life Impact, and Healthcare Use](https://medichelpline.com/clinical-feed/bmj-open-7-multiple-long-term-conditions-and-their-association-with-quality-of-life-and.md)
- [New oral anticoagulants linked to slower cognitive decline in Alzheimer’s patients with AFib](https://medichelpline.com/clinical-feed/medical-news-today-0-new-oral-anticoagulants-may-help-slow-cognitive-decline-in-alzheimer-s-disease.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.